<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children - Brodlie, M - 2015 | Cochrane Library</title> <meta content="Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children - Brodlie, M - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008202.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children - Brodlie, M - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008202.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008202.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children" name="citation_title"/> <meta content="Malcolm Brodlie" name="citation_author"/> <meta content="Newcastle University and Great North Children's Hospital" name="citation_author_institution"/> <meta content="malcolm.brodlie@ncl.ac.uk" name="citation_author_email"/> <meta content="Atul Gupta" name="citation_author"/> <meta content="Royal Brompton Hospital &amp; Imperial College London, MRC &amp; Asthma UK Centre in Allergic Mechanisms of Asthma" name="citation_author_institution"/> <meta content="Carlos E Rodriguez‐Martinez" name="citation_author"/> <meta content="Universidad Nacional de Colombia" name="citation_author_institution"/> <meta content="Jose A Castro‐Rodriguez" name="citation_author"/> <meta content="Pontificia Universidad Católica de Chile" name="citation_author_institution"/> <meta content="Francine M Ducharme" name="citation_author"/> <meta content="Michael C McKean" name="citation_author"/> <meta content="Newcastle upon Tyne NHS Trust" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD008202.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/10/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008202.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008202.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008202.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acetates [*therapeutic use]; Common Cold [complications, virology]; Cyclopropanes; Leukotriene Antagonists [*therapeutic use]; Maintenance Chemotherapy [methods]; Quinolines [*therapeutic use]; Randomized Controlled Trials as Topic; Respiratory Sounds [*drug effects]; Respiratory Tract Infections [*complications]; Sulfides; Time Factors; Virus Diseases [*complications]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008202.pub2&amp;doi=10.1002/14651858.CD008202.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="ZCrlluee";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008202\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008202\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008202\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008202\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","hr","fr","zh_HANS","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008202.pub2",title:"Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children",firstPublishedDate:"Oct 19, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZCrlluee&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008202.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008202.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008202.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008202.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008202.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008202.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008202.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008202.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008202.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008202.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3969 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008202.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/full#CD008202-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/full#CD008202-sec-0131"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/full#CD008202-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/full#CD008202-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/full#CD008202-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/full#CD008202-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/full#CD008202-sec-0068"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/full#CD008202-sec-0125"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/appendices#CD008202-sec-0136"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/table_n/CD008202StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/table_n/CD008202StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Leukotriene receptor antagonists as maintenance and intermittent therapy for episodic viral wheeze in children </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/information#CD008202-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Malcolm Brodlie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/information#CD008202-cr-0003">Atul Gupta</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/information#CD008202-cr-0004">Carlos E Rodriguez‐Martinez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/information#CD008202-cr-0005">Jose A Castro‐Rodriguez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/information#CD008202-cr-0006">Francine M Ducharme</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008202.pub2/information#CD008202-cr-0007">Michael C McKean</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/information/en#CD008202-sec-0145">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 October 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008202.pub2">https://doi.org/10.1002/14651858.CD008202.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008202-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008202-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008202-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008202-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008202-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008202-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008202-abs-0001" lang="en"> <section id="CD008202-sec-0001"> <h3 class="title" id="CD008202-sec-0001">Background</h3> <p>Episodic viral wheeze (EVW) associated with viral respiratory tract infections is a common reason for pre‐school children to utilise health care resources and for carers to take time away from employment. About a third of children experience a wheezing episode before the age of five years. EVW therefore represents a significant public health problem. Many pre‐school children only wheeze in association with viral infections and in such cases EVW appears to be a separate entity from atopic asthma. Some trials have explored the effectiveness of leukotriene receptor antagonists (LTRAs) as regular (maintenance) or episodic (intermittent) treatment in this context. </p> </section> <section id="CD008202-sec-0002"> <h3 class="title" id="CD008202-sec-0002">Objectives</h3> <p>To evaluate the evidence for the efficacy and safety of maintenance and intermittent LTRAs in the management of EVW in children aged one to six years. </p> </section> <section id="CD008202-sec-0003"> <h3 class="title" id="CD008202-sec-0003">Search methods</h3> <p>We searched the Cochrane Airways Group register of trials with pre‐specified terms. We performed additional searches by consulting the authors of identified trials, online trial registries of manufacturers' web sites, and reference lists of identified primary papers and reviews. Search results are current to June 2015. </p> </section> <section id="CD008202-sec-0004"> <h3 class="title" id="CD008202-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials with a parallel‐group or cross‐over (for intermittent LTRA only) design. Maintenance was considered as treatment for more than two months and intermittent as less than 14 days. EVW was defined as a history of at least one previous episode of wheezing in association with a viral respiratory tract infection in the absence of symptoms between episodes. As far as possible, relevant specific data were obtained from authors of studies that included children of a wider age group or phenotype.   </p> </section> <section id="CD008202-sec-0005"> <h3 class="title" id="CD008202-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed studies for inclusion in the review and assessed risk of bias. The primary outcome was number of children with one or more viral‐induced episodes requiring one or more treatments with rescue oral corticosteroids. We analysed combined continuous data outcomes with the mean difference and dichotomous data outcomes with an odds ratio (OR). </p> </section> <section id="CD008202-sec-0006"> <h3 class="title" id="CD008202-sec-0006">Main results</h3> <p>We identified five studies eligible for inclusion in the review (one investigated maintenance treatment, three intermittent therapy and one had both maintenance and intermittent treatment arms) these included 3741 participants. Each study involved oral montelukast and was of good methodological quality, but differed in choice of outcome measures thus limiting our ability to aggregate data across studies. Only primary outcome and adverse event data are reported in this abstract. </p> <p>For maintenance treatment, specific data obtained from a single study, pertaining to children with only an EVW phenotype, showed no statistically significant group reduction in the number of episodes requiring rescue oral corticosteroids associated with daily montelukast versus placebo (OR 1.20, 95% CI 0.70 to 2.06, moderate quality evidence). </p> <p>For intermittent LTRA, pooled data showed no statistically significant reduction in the number of episodes requiring rescue oral steroids in children treated with LTRA versus placebo (OR 0.77, 95% CI 0.48 to 1.25, moderate quality evidence). Specific data for children with an EVW phenotype obtained from a single study of intermittent montelukast treatment showed a small, but statistically significant reduction in unscheduled medical attendances due to wheeze (RR 0.83, 95% CI 0.71 to 0.98). </p> <p>For maintenance compared to intermittent LTRA treatment no data relating to the primary outcome of the review were identified. </p> <p>There were no other significant group differences identified in other secondary efficacy outcomes for maintenance or intermittent LTRA treatment versus placebo, or maintenance versus intermittent LTRA treatment. We collected descriptive data on adverse events as reported by four of the five included studies, and rates were similar between treatment and placebo groups. </p> <p>Potential heterogeneity in the phenotype of participants within and across trials is a limitation of the evidence. </p> </section> <section id="CD008202-sec-0007"> <h3 class="title" id="CD008202-sec-0007">Authors' conclusions</h3> <p>In pre‐school children with EVW, there is no evidence of benefit associated with maintenance or intermittent LTRA treatment, compared to placebo, for reducing the number of children with one or more viral‐induced episodes requiring rescue oral corticosteroids, and little evidence of significant clinical benefit for other secondary outcomes. Therefore until further data are available, LTRA should be used with caution in individual children. When used, we suggest a therapeutic trial is undertaken, during which efficacy should be carefully monitored. It is likely that children with an apparent EVW phenotype are not a homogeneous group and that subgroups may respond to LTRA treatment depending on the exact patho‐physiological mechanisms involved. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008202-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008202-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD008202-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD008202-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008202-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008202-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008202-abs-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008202-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008202-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008202-abs-0004" lang="en"> <h3>What is the evidence for benefit from leukotriene receptor antagonists in pre‐school children who wheeze when they have a cold? </h3> <p><b>Background to the review</b> </p> <p>Acute episodes of wheezing in pre‐school aged children are common. Many children in this age group seem to wheeze only when they have a common cold‐type virus with no ongoing symptoms between episodes, unlike older children with allergic‐type asthma. Acute episodes of wheezing cause the child to breathe more quickly than normal and they may require supportive treatment such as the use of rescue inhalers; in moderate or severe episodes they may also need a short course of oral steroids and not uncommonly may require treatment in hospital and supplemental oxygen. Their carers may need to take time off work to look after children who are unwell. Although episodic wheezing with viruses is a common problem, there is controversy about the best way to prevent or shorten episodes. </p> <p>Leukotriene receptor antagonists (LTRAs) are drugs that are taken by mouth and work by reducing inflammation and allergic reactions in the airways. </p> <p><b>Aim of the review</b> </p> <p>In this review, we have combined the evidence from the different studies comparing the maintenance (regular) or intermittent (just during episodes of wheeze with viruses) use of LTRAs with placebo in episodic viral wheezing in pre‐school children. </p> <p><b>What did we find?</b> </p> <p>We identified five eligible studies that varied in their choice of outcomes and therefore limited our ability to combine the findings between different studies. We failed to find any evidence of benefit of maintenance or intermittent LTRA treatment over placebo for preventing acute episodes of wheezing requiring use of rescue oral steroids, and little evidence of clinical benefit in other outcomes. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008202-sec-0131" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008202-sec-0131"></div> <h3 class="title" id="CD008202-sec-0132">Implications for practice</h3> <section id="CD008202-sec-0132"> <p>Acute episodes of EVW in pre‐school children are common, are associated with significant morbidity, and place a substantial burden on healthcare resources and society as a whole. Despite well designed trials, there is little available evidence of significant clinical benefit from either maintenance or intermittent LTRA therapy compared to placebo in pre‐school children with EVW. Therefore until further data are available, LTRA should be used with caution in individual children with EVW. When used, a therapeutic trial is suggested during which efficacy should be carefully monitored. </p> </section> <h3 class="title" id="CD008202-sec-0133">Implications for research</h3> <section id="CD008202-sec-0133"> <p>It is likely that children with an apparent EVW phenotype are not a homogeneous group and that subgroups could respond to specific therapies dependent on the exact patho‐physiological mechanisms involved. In light of the results of this systematic review, a number of unanswered research questions remain that should be addressed by future high‐quality studies. </p> <p> <ol id="CD008202-list-0012"> <li> <p>Careful phenotyping or genotyping or both of children, using consistent and agreed criteria, entering future studies is essential. </p> </li> <li> <p>Participants in studies should be followed up prospectively for a longer period (12 months or more) to document response to therapy and ascertain the evolution of different wheezing phenotypes. </p> </li> <li> <p>Head‐to‐head comparisons between intermittent and maintenance LTRA and between intermittent LTRA versus intermittent inhaled corticosteroids should be studied. Stratified randomisation and reporting on those with moderate and severe episodes (previously requiring rescue oral steroids or hospital admission) versus those with mild wheezing episodes (not previously requiring rescue oral steroids or hospital admission) should be considered to clarify the impact in children with different severity of episodes. </p> </li> <li> <p>Consideration should be given to what are the most clinically relevant outcome measures in trials of interventions for children with EVW depending on their prior severity. For example, it is arguable that the use of rescue oral corticosteroids may not be the most appropriate primary outcome measure given current debate about their efficacy in EVW. Other measures such as use of bronchodilators, symptom scores, healthcare resource utilisation or time off school or nursery for children or off work for parents or caregivers should be considered. </p> </li> <li> <p>Identification of subgroups of children who are most likely to respond to LTRA therapy. Cluster analysis of large, routinely collected data sets may also help to identify characteristics of children who respond to LTRA treatment. </p> </li> </ol> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008202-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008202-sec-0036"></div> <div class="table" id="CD008202-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Maintenance LTRA compared to placebo for episodic viral wheeze in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Maintenance LTRA compared to placebo for episodic viral wheeze in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> episodic viral wheeze in children<br/> <b>Settings:</b> community and hospitals<br/> <b>Intervention: m</b> aintenance LTRA<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Maintenance LTRA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants experiencing one or more episode requiring treatment with oral steroids </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>173 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>201 per 1000<br/> (128 to 302) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.20<br/> (0.70 to 2.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>347<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants experiencing one or more episodes requiring ED visit</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000<br/> (75 to 208) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.66<br/> (0.37 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>347<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants experiencing one or more episodes requiring hospital admission</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000<br/> (12 to 93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.65<br/> (0.23 to 1.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>347<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals ‐ Total number of withdrawals</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>154 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>137 per 1000<br/> (107 to 171) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.87<br/> (0.66 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1729<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None reported, so not possible to assess the risks of serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Confidence interval cannot rule out important benefit or harm. </p> <p><sup>2</sup>Note potential heterogeneity in the phenotype of participants within and across studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008202-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intermittent LTRA compared to placebo for episodic viral wheeze in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intermittent LTRA compared to placebo for episodic viral wheeze in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> episodic viral wheeze in children<br/> <b>Settings:</b> community and hospitals<br/> <b>Intervention: i</b> ntermittent LTRA<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Intermittent LTRA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants experiencing one or more episode requiring treatment with oral steroids </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>336 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>285 per 1000<br/> (215 to 382) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.85<br/> (0.64 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>343<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants experiencing one or more episodes requiring ED visit</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>553 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>553 per 1000<br/> (378 to 714) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/> (0.49 to 2.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants experiencing one or more episodes requiring hospital admission</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 1000<br/> (18 to 203) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.73<br/> (0.20 to 2.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals ‐ Total number of withdrawals</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>188 per 1000<br/> (151 to 232) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.03<br/> (0.79 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1402<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None reported, so not possible to assess the risks of serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Confidence interval cannot rule out important benefit or harm. </p> <p><sup>2</sup>Note potential heterogeneity in the phenotype of participants within and across studies. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008202-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008202-sec-0037"></div> <section id="CD008202-sec-0038"> <h3 class="title" id="CD008202-sec-0038">Description of the condition</h3> <p>Around a third of children experience at least one episode of wheeze before the age of five years (<a href="./references#CD008202-bbs2-0039" title="KuehniCE , DavisA , BrookeAM , SilvermanM . Are all wheezing disorders in very young (preschool) children increasing in prevalence?. Lancet2001;358:1821‐1825. ">Kuehni 2001</a>). Evidence suggests that in pre‐school aged children recurrent wheezing that occurs exclusively in association with viral infection of the respiratory tract may represent a separate entity from atopic asthma (<a href="./references#CD008202-bbs2-0050" title="SilvermanM . Out of the mouths of babes and sucklings: lessons from early childhood asthma. Thorax1993;48:1200‐4. ">Silverman 1993</a>; <a href="./references#CD008202-bbs2-0051" title="SpycherBD , SilvermanM , BrookeAM , MinderCE , KuehniCE . Distinguishing phenotypes of childhood wheeze and cough using latent class analysis. European Respiratory Journal2008;31(5):974‐81. ">Spycher 2008</a>). This phenomenon is known as episodic viral wheezing (EVW). </p> <p>A considerable number of children require emergency treatment or admission to hospital, or both for EVW placing a significant burden on healthcare resources and society as a whole (<a href="./references#CD008202-bbs2-0021" title="AndersonHR . Epiddmiology of asthma. British Journal of Hospital Medicine1992;47:99‐104. ">Anderson 1992</a>; <a href="./references#CD008202-bbs2-0040" title="LougheedMD , GarveyN , ChapmanKR , CicuttoL , DalesR , DayAG , et al. The Ontario asthma regional variation study: emergency department visit rates and the relation to hospitalization rates. Chest2006;129(4):909‐17. ">Lougheed 2006</a>, <a href="./references#CD008202-bbs2-0027" title="DaviesG , PatonJY , BeatonSJ , YoungD , LenneyW . Children admitted with acute wheeze/asthma during November 1998–2005: a national UK audit. Archives of Disease in Childhood2008;93:952‐958. ">Davies 2008</a>, <a href="./references#CD008202-bbs2-0032" title="DucharmeFM , TseSM , ChauhanB . Diagnosis, management, and prognosis of preschool wheeze. Lancet2014;383:1593‐604. ">Ducharme 2014</a>). The evidence base for managing children with EVW is generally thin and acute treatments are largely supportive such as oxygen therapy and inhaled bronchodilators (<a href="./references#CD008202-bbs2-0026" title="BushA . Practice imperfect ‐ treatment for wheezing in preschoolers. New England Journal of Medicine2009;360(4):409‐410. ">Bush 2009</a>; <a href="./references#CD008202-bbs2-0042" title="McKeanM , DucharmeF . Inhaled steroids for episodic viral wheeze of childhood. Cochrane Database of Systematic Reviews2000, Issue 1. [DOI: 10.1002/14651858.CD001107] ">McKean 2000</a>). A double‐blind, placebo‐controlled, randomised trial found no clinical benefit from treatment with oral corticosteroids in children presenting to hospital with acute wheeze in association with a viral infection (<a href="./references#CD008202-bbs2-0045" title="PanickarJ , LakhanpaulM , LambertPC , KeniaP , StephensonT , SmythA , et al. Oral prednisolone for preschool children with acute virus‐induced wheezing. New England Journal of Medicine2009;360(4):329‐38. ">Panickar 2009</a>). In another study high‐dose inhaled fluticasone initiated at the start of a viral respiratory tract infection was associated with some reduction in the duration of symptoms, but also a reduced increase in height. (<a href="./references#CD008202-bbs2-0030" title="DucharmeFM , LemireC , NoyaFJ , DavisGM , AlosN , LeblondH , et al. Preemptive use of high‐dose fluticasone for virus‐induced wheezing in young children. New England Journal of Medicine2009;360:409‐10. ">Ducharme 2009</a>). </p> <p>EVW is largely a disease of pre‐school children with the majority of children affected aged one to three years (<a href="./references#CD008202-bbs2-0031" title="DucharmeFM , MorinJ , DavisGM , GingrasJ , NoyaFJ . High physician adherence to phenotype‐specific asthma guidelines, but large variability in phenotype assessment in children. Current Medical Research and Opinion2012;28(9):1561‐70. ">Ducharme 2012</a>, <a href="./references#CD008202-bbs2-0041" title="MartinezFD , WrightAL , TaussigLM , HolbergCJ , HalonenM , MorganWJ . Asthma and wheezing in the first six years of life. New England Journal of Medicine1995;19:133‐8. ">Martinez 1995</a>; <a href="./references#CD008202-bbs2-0051" title="SpycherBD , SilvermanM , BrookeAM , MinderCE , KuehniCE . Distinguishing phenotypes of childhood wheeze and cough using latent class analysis. European Respiratory Journal2008;31(5):974‐81. ">Spycher 2008</a>; <a href="./references#CD008202-bbs2-0052" title="SteinRT , HolbergCJ , MorganWJ , WrightAL , LombardiE , TaussigL , et al. Peak flow variability, methacholine responsiveness and atopy as markers for detecting different wheezing phenotypes in childhood. Thorax1997;52(11):946‐52. ">Stein 1997</a>; <a href="./references#CD008202-bbs2-0055" title="WilsonNM . The significance of early wheezing. Clinical and Experimental Allergy1994;24(6):522‐9. ">Wilson 1994</a>). The natural history and progression of pre‐school children who wheeze is complex. Several cohort studies suggest different trajectories, including 'transient wheezers' who experience EVW as young children but whose symptoms resolve by school age, 'persistent wheezers' with multiple risk factors who evolve from an EVW phenotype as young children to an atopic asthma, multi‐trigger wheeze, phenotype as school‐aged children, in addition to 'late‐onset wheezers' who first experience symptoms of atopic asthma after the age of three years (<a href="./references#CD008202-bbs2-0041" title="MartinezFD , WrightAL , TaussigLM , HolbergCJ , HalonenM , MorganWJ . Asthma and wheezing in the first six years of life. New England Journal of Medicine1995;19:133‐8. ">Martinez 1995</a>; <a href="./references#CD008202-bbs2-0047" title="SavenijeOE , GranellR , CaudriD , KoppelmanGH , SmitHA , WijgaA , et al. Comparison of childhood wheezing phenotypes in 2 birth cohorts: ALSPAC and PIAMA. Journal of Allergy and Clinical Immunology2011;127(6):1505‐12. ">Savenije 2011</a>; <a href="./references#CD008202-bbs2-0051" title="SpycherBD , SilvermanM , BrookeAM , MinderCE , KuehniCE . Distinguishing phenotypes of childhood wheeze and cough using latent class analysis. European Respiratory Journal2008;31(5):974‐81. ">Spycher 2008</a>). An overall paradigm encompassing these studies is that EVW is intermittent in nature, occurs predominantly in pre‐school children and represents a separate entity from atopic asthma, where wheeze is associated with multiple environmental triggers and mediated by allergic mechanisms. </p> </section> <section id="CD008202-sec-0039"> <h3 class="title" id="CD008202-sec-0039">Description of the intervention</h3> <p>In this systematic review we evaluate the available evidence for the efficacy of maintenance (regular as preventive treatment) and intermittent (during symptomatic episodes) leukotriene receptor antagonists (LTRAs) in the management of children aged between one and six years seemingly presenting with EVW. </p> </section> <section id="CD008202-sec-0040"> <h3 class="title" id="CD008202-sec-0040">How the intervention might work</h3> <p>Leukotrienes are pro‐inflammatory mediators that are produced by a range of cells, including eosinophils, mast cells and alveolar macrophages, in response to stimuli in the airway. Leukotrienes are derived from arachidonic acid by way of the 5‐lipoxygenase pathway. The cysteinyl leukotrienes (C4, D4 and E4) bind to highly selective receptors and induce bronchoconstriction, eosinophil chemotaxis, tissue oedema and increased mucus secretion (<a href="./references#CD008202-bbs2-0029" title="DrazenJM , IsraelE , O'ByrnePM . Treatment of asthma with drugs modifying the leukotriene pathway. New England Journal of Medicine1999;340:197‐206. ">Drazen 1999</a>). The most commonly prescribed LTRA is montelukast, which blocks cysteinyl leukotriene receptors and, when given regularly, is of proven benefit in pre‐school children with persistent wheeze, albeit less effective than low doses of inhaled corticosteroids (<a href="./references#CD008202-bbs2-0025" title="British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. A national clinical guideline. http://www.sign.ac.uk/pdf/SIGN141.pdf2014. ">BTS 2014</a>; <a href="./references#CD008202-bbs2-0034" title="Global Initiative forAsthma . Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org/2012. ">GINA 2012</a>; <a href="./references#CD008202-bbs2-0011" title="KnorrB , FranchiLM , BisgaardH , VermeulenJH , LeSouefP , SantanelloN , et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics2001;108(3):E48. ">Knorr 2001</a>). Oomen and Grigg measured urinary leukotriene E4 and serum total immunoglobulin E (IgE) in preschool children with EVW during an acute attack (<a href="./references#CD008202-bbs2-0044" title="OommenA , GriggJ . Urinary leukotriene E4 in preschool children with acute clinical viral wheeze. European Respiratory Journal2003;21:149‐54. ">Oommen 2003</a>). They found heterogeneity in urinary leukotriene E4 excretion. Elevated urinary leukotriene E4 levels occurred in 23 of the 44 children studied with the highest IgE levels. Increased cysteinyl leukotriene production may therefore be clinically relevant to this subgroup of children; alternatively however it is possible that they may have identified a group of children with multi‐trigger atopic asthma, incorrectly perceived to have EVW. </p> </section> <section id="CD008202-sec-0041"> <h3 class="title" id="CD008202-sec-0041">Why it is important to do this review</h3> <p>LTRAs are prescribed by clinicians for children with EVW, however, the evidence‐base supporting this intervention is unclear and the question <i>'What evidence exists for clinical efficacy of LTRAs in children with EVW  either regularly or at the onset of viral respiratory tract infections?'</i> is a pertinent one. This is the first Cochrane Review to address this issue. We focus on young children as this is the age group where EVW is most recognised, causes the most morbidity and is therefore most clinically relevant. In children with EVW, acute episodes only occur in association with viral respiratory tract infections, with no interval symptoms or other triggers (<a href="./references#CD008202-bbs2-0022" title="BacharierLB , BonerA , CarlsenKH , EigenmannPA , FrischerT , GötzM , et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy2008;63(1):5‐34. ">Bacharier 2008</a>; <a href="./references#CD008202-bbs2-0024" title="BrandPL , BaraldiE , BisgaardH , BonerAL , Castro‐RodriguezJA , CustovicA , et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence‐based approach. European Respiratory Journal2008;32(4):1096‐1110. ">Brand 2008</a>). To distinguish young children with EVW from those with atopic asthma may be challenging in 'real life' however because most children become more symptomatic during viral respiratory tract infections and interval symptoms, as reported by a third party, are not always evident (<a href="./references#CD008202-bbs2-0031" title="DucharmeFM , MorinJ , DavisGM , GingrasJ , NoyaFJ . High physician adherence to phenotype‐specific asthma guidelines, but large variability in phenotype assessment in children. Current Medical Research and Opinion2012;28(9):1561‐70. ">Ducharme 2012</a>). To try and address this issue we carefully sought to only include studies that involved children with an EVW phenotype in this systematic review. It is also important to note that EVW represents a separate entity from viral bronchiolitis, which is recognised in infants (younger than 12 months of age) and is associated predominantly with crackles on auscultation (<a href="./references#CD008202-bbs2-0056" title="ØymarK , SkjervenHO , MikalsenIB . Acute bronchiolitis in infants, a review. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine2014;22:23. ">Øymar 2014</a>; <a href="./references#CD008202-bbs2-0049" title="Scottish Intercollegiate Guidelines Network. Bronchiolitis in children. A national clinical guideline. www.sign.ac.uk/pdf/sign91.pdf2006. ">SIGN 2006</a>). We chose, 'number of children with one or more viral‐induced episodes requiring one or more treatment with rescue oral corticosteroids' as the primary outcome when devising our review protocol. It may be argued that the use of oral corticosteroids in the management of EVW has recently been debated (<a href="./references#CD008202-bbs2-0023" title="BeigelmanA , BacharierLB . Infection‐induced wheezing in young children. Journal of Allergy and Clinical Immunology.2014;133(2):603‐4. ">Beigelman 2014</a>; <a href="./references#CD008202-bbs2-0026" title="BushA . Practice imperfect ‐ treatment for wheezing in preschoolers. New England Journal of Medicine2009;360(4):409‐410. ">Bush 2009</a>; <a href="./references#CD008202-bbs2-0045" title="PanickarJ , LakhanpaulM , LambertPC , KeniaP , StephensonT , SmythA , et al. Oral prednisolone for preschool children with acute virus‐induced wheezing. New England Journal of Medicine2009;360(4):329‐38. ">Panickar 2009</a>; <a href="./references#CD008202-bbs2-0053" title="TalA , LevyN , BearmanJE . Methylprednisolone therapy for acute asthma in infants and toddlers: a controlled clinical trial. Pediatrics1990;86(3):350‐6. ">Tal 1990</a>) however they remain a marker of moderate and severe episodes and a comprehensive range of secondary outcomes were also assessed. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008202-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008202-sec-0042"></div> <p>To evaluate the evidence for the efficacy and safety of maintenance and intermittent LTRAs in the management of EVW in children aged one to six years. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008202-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008202-sec-0043"></div> <section id="CD008202-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008202-sec-0045"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs), parallel‐group and cross‐over (intermittent only) studies were considered for this review. </p> </section> <section id="CD008202-sec-0046"> <h4 class="title">Types of participants</h4> <p> <ol id="CD008202-list-0001"> <li> <p>Children aged one to six years with EVW were included. EVW was defined by the following criteria:    </p> <ol id="CD008202-list-0002"> <li> <p>history of at least one reported episode of wheezing in association with clinical evidence of a viral respiratory tract infection (confirmation of virus by serology, culture or antigen assay not necessary);     </p> </li> <li> <p>no symptoms between exacerbations.</p> </li> </ol> </li> <li> <p>Exclusion criteria were:</p> <ol id="CD008202-list-0003"> <li> <p>children with cystic fibrosis, bronchopulmonary dysplasia or any other chronic lung disease;      </p> </li> <li> <p>children with bacterial pneumonia;     </p> </li> <li> <p>children with viral bronchiolitis (children younger than 12 months were excluded to avoid infants with viral bronchiolitis, i.e. the presence of crackles or the first or second episode of wheeze in a child less than 12 months); </p> </li> <li> <p>children with atopic or multi‐trigger asthma defined by episodes of wheeze caused by a range of stimuli other than viruses; </p> </li> <li> <p>children who wheeze with viral respiratory illnesses and have interval symptoms between viral infections. </p> </li> </ol> </li> </ol> </p> </section> <section id="CD008202-sec-0047"> <h4 class="title">Types of interventions</h4> <p>Participants must have been randomised to receive a LTRA, within the licensed dose range, as maintenance (treatment for &gt; 2 months) or intermittent (treatment for &lt; 14 days at the onset of a viral‐induced episode) therapy versus placebo. </p> <p>We assessed the effects of LTRAs in three planned comparisons.</p> <p> <ol id="CD008202-list-0004"> <li> <p>Maintenance (regular) LTRA therapy versus placebo.</p> </li> <li> <p>Intermittent (episodic) LTRA therapy versus placebo.</p> </li> <li> <p>Maintenance LTRA therapy versus intermittent LTRA therapy.</p> </li> </ol> </p> </section> <section id="CD008202-sec-0048"> <h4 class="title">Types of outcome measures</h4> <p>The following categories of outcome measures were considered important in establishing whether LTRAs have a role to play in secondary prevention of EVW. </p> <section id="CD008202-sec-0049"> <h5 class="title">Primary outcomes</h5> <p>Number of children with one or more viral‐induced episodes requiring one or more treatments with rescue oral corticosteroids. </p> </section> <section id="CD008202-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD008202-list-0005"> <li> <p>Number of viral‐induced episodes requiring treatment with oral corticosteroids by treatment group (adjusting for the number of viral respiratory tract infections and the intraclass correlation for clustering of infections within individual children, if feasible). </p> </li> <li> <p>Indicators of the severity of episodes.</p> <ol id="CD008202-list-0006"> <li> <p>Number of children with one or more viral‐induced episodes requiring one or more emergency department or emergency doctor visits. </p> </li> <li> <p>Number of children with one or more viral‐induced episodes requiring hospital admission.</p> </li> <li> <p>Group mean symptom scores during episodes (adjusting for the number of viral respiratory tract infections and the intraclass correlation for clustering of infections within individual children, if feasible). </p> </li> <li> <p>Group mean use of rescue bronchodilator during episodes (adjusting for the number of viral respiratory tract infections and the intraclass correlation for clustering of infections within individual children, if feasible). </p> </li> <li> <p>New prescription or increased dosage of inhaled corticosteroids or other maintenance add‐on therapy. </p> </li> </ol> </li> <li> <p>Indicators of duration of episodes by group (adjusting for the number of viral respiratory tract infections and the intraclass correlation for clustering of infections within individual children, if feasible). </p> <ol id="CD008202-list-0007"> <li> <p>Duration of lower respiratory tract symptoms (dyspnoea, cough and wheeze).</p> </li> <li> <p>Duration of bronchodilator use.</p> </li> <li> <p>Length of emergency department stay.</p> </li> <li> <p>Length of hospital stay.</p> </li> </ol> </li> <li> <p>Adverse health events.</p> <ol id="CD008202-list-0008"> <li> <p>Patients with any, as well as specific, adverse effects (growth, headache, etc.).</p> </li> </ol> </li> <li> <p>Withdrawals.</p> <ol id="CD008202-list-0009"> <li> <p>Patients withdrawn for any reason, because of poor response and because of adverse health effects, respectively. </p> </li> </ol> </li> <li> <p>Indicators of frequency ‐ for maintenance treatment (adjusting for the number of viral respiratory tract infections and the intraclass correlation for clustering of infections within individual children, if feasible). </p> <ol id="CD008202-list-0010"> <li> <p>Frequency of EVW episodes.</p> </li> <li> <p>Frequency of lower respiratory tract symptoms suggestive of asthma (dyspnoea, wheeze, cough). </p> </li> </ol> </li> </ol> </p> </section> </section> </section> <section id="CD008202-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008202-sec-0052"> <h4 class="title">Electronic searches</h4> <p>We identified trials from the Cochrane Airways Group Specialised Register of trials (CAGR), which is derived from systematic searches of bibliographic databases including the Cochrane Central Register of Controlled Trials (CENTRAL) (<i>The Cochrane Library</i>), MEDLINE, EMBASE, CINAHL, AMED, and PsycINFO, and handsearching of respiratory journals and meeting abstracts (please see <a href="./appendices#CD008202-sec-0137">Appendix 1</a> for further details) until the end of June 2015. All records in the CAGR coded as 'asthma' were searched using the following terms: </p> <p>(wheez* or episodic or viral* or virus* or evw ) AND (leukotriene* or leukotriene* or ltra or anti‐leukotriene* or anti‐leucotriene* or anti‐leuk* or "anti leuk*" or anti‐leuc* or "anti leuc*" or *lukast or lukast* or montelukast* or singulair or zafirlukast* or accolate or pranlukast* or ultair) </p> <p>We also conducted a search of ClinicalTrials.gov (www.clinicaltrials.gov/). All databases were searched from their inception to June 2015 and there was no restriction on language of publication. </p> </section> <section id="CD008202-sec-0053"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of all primary studies and review articles for additional references. We contacted authors of identified trials and asked them to identify other published and unpublished studies. We also contacted manufacturers and experts in the field. </p> </section> </section> <section id="CD008202-sec-0054"> <h3 class="title" id="CD008202-sec-0054">Data collection and analysis</h3> <section id="CD008202-sec-0055"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MB and AG) from our team selected studies as being potentially relevant based on a review of the titles and abstracts, if available. The complete text of these studies was retrieved and reviewed independently by the same reviewers. Disagreement as to which papers to include was resolved by consensus. Where there was a lack of consensus, a third reviewer (MCM) determined the final decision. Full reports were obtained for trials appearing to meet the inclusion criteria or for which there was insufficient information in the title and abstract to make a clear decision. </p> </section> <section id="CD008202-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MB and AG) independently extracted data using specially designed data extraction forms. Data extraction forms were pilot‐tested to ensure clarity, completeness and ease of use.<br/> The characteristics of the trial participants, interventions and outcomes for the included trials were presented in study tables. Authors were contacted for clarification or further information. We accepted data from groups of children who were eligible, as per our protocol, who were included within studies that covered a larger age span or involved patients (such as those with interim symptoms) who would have been excluded as per our protocol. </p> </section> <section id="CD008202-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MB and AG) independently assessed the design of eligible studies in terms of bias protection. Any discordance between the authors was discussed and resolved by consensus. Where there was lack of consensus, a third reviewer (MCM) determined the final decision. Where methodological issues were unclear, we attempted to contact the corresponding author of the original paper for clarification. </p> <p>We identified and present information pertaining to the following potential sources of bias. </p> <p> <ol id="CD008202-list-0011"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ol> </p> <p>We provided judgements for each of these domains alongside the descriptions of study methodology using The Cochrane Collaboration’s tool for assessing risk of bias (<a href="./references#CD008202-bbs2-0037" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011a</a>). </p> </section> <section id="CD008202-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <section id="CD008202-sec-0059"> <h5 class="title">Continuous data</h5> <p>Data for parallel group trials were expressed as mean difference (MD) and 95% confidence intervals (CI). We pooled data from crossover studies with generic inverse variance (GIV) (<a href="./references#CD008202-bbs2-0038" title="HigginsJPT , DeeksJJ , Altman DG(editors) . Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011b</a>). For continuous data variables extracted from crossover studies (intermittent LTRA use only), we used the mean differences (MD) and estimated the standard errors (SE) based upon the published P value, or from 95% CI if available. Where these were not available, we used the published standard deviations (SDs) for the two groups to derive a SE. </p> <p>A standardised mean difference (SMD) was calculated when studies had measured the same outcome but with different metrics (e.g. for pooling data from different symptom scores). For GIV outcomes reporting SD units, we expressed effect sizes in terms of the pooled standard deviation for each study (e.g. where the effect size for a given study is 0.5, this represented a mean difference between the treatment and control groups of half a pooled standard deviation as reported in that study). </p> </section> <section id="CD008202-sec-0060"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous variables (e.g. admission to hospital), we calculated relative risks as these are easier to interpret clinically. An odds ratio (OR) was calculated based on the event rate in the studies for the number needed to treat for an additional beneficial outcome (NNTB) and the number needed to treat for an additional harmful outcome (NNTH). NNTB &amp; NNTH were calculated using an online statistical package (<a href="./references#CD008202-bbs2-0054" title="CatesCJ . Visual Rx 2.3. Dr Christopher Cates www.nntonline.net, 2008. ">Visual Rx</a>). </p> <p>Data were pooled using a fixed‐effect model (FE), unless heterogeneity was identified (<a href="./references#CD008202-bbs2-0028" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> </section> </section> <section id="CD008202-sec-0061"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the patient.</p> </section> <section id="CD008202-sec-0062"> <h4 class="title">Dealing with missing data</h4> <p>We noticed in previous reviews that some papers do not report the spread of data in a format that allows meta‐analysis, for example, not reporting standard deviations. Where possible we used established techniques for estimating standard deviations or 95% CI in order for us to include all eligible studies in the analysis. </p> <p>Where only one study presented data in a usable form, we entered the data into Review Manager 5.3 (<a href="./references#CD008202-bbs2-0046" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), but reported the statistics from the published paper. </p> </section> <section id="CD008202-sec-0063"> <h4 class="title">Assessment of heterogeneity</h4> <p>We tested heterogeneity using the I<sup>2</sup> statistic, which measures the extent of heterogeneity not attributable to the play of chance (<a href="./references#CD008202-bbs2-0036" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>). Where the I<sup>2</sup> statistic exceeds 30%, random‐effects modelling was applied in order to determine whether the pooled effect estimate was altered (<a href="./references#CD008202-bbs2-0028" title="DeeksJJ , HigginsJPT , Altman DG(editors) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> </section> <section id="CD008202-sec-0064"> <h4 class="title">Assessment of reporting biases</h4> <p>We used funnel plots to assess the presence of publication bias for trials contributing data to the main outcomes (<a href="./references#CD008202-bbs2-0033" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315:629‐34. ">Egger 1997</a>). </p> </section> <section id="CD008202-sec-0065"> <h4 class="title">Data synthesis</h4> <p>We extracted data for trials and entered them into Review Manager Version 5.3 (<a href="./references#CD008202-bbs2-0046" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> <section id="CD008202-sec-0066"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If possible, we aimed to explore the effect of atopy as a subgroup analysis (atopy versus non atopy ‐ on a basis of two or more positive RAST tests or skin prick tests, &gt; 3 mm wheal above control), and the impact of age groups (age one to three years vs. four to six years). We tested differences between subgroups with a test for interaction (<a href="./references#CD008202-bbs2-0020" title="AltmanD , JMBland . Statistics Notes: Interaction revisited: the difference between two estimates. BMJ2003;326:219. ">Altman 2003</a>). In addition, we reported the percentage of children with atopy in each trial and performed a sensitivity analysis, whereby trials where atopy exceeded 20% were excluded. </p> </section> <section id="CD008202-sec-0067"> <h4 class="title">Sensitivity analysis</h4> <p>We performed a sensitivity analysis to examine the effect of methodological quality on the pooled estimate after removing studies that were deemed not to have optimally addressed the sources of bias detailed above. We also removed studies which reported incomplete data for the primary outcome in the review as a sensitivity analysis. </p> <p>We planned to perform a sensitivity analysis whereby trials where atopy exceeded 20% were excluded. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008202-sec-0068" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008202-sec-0068"></div> <section id="CD008202-sec-0069"> <h3 class="title">Description of studies</h3> <p>Please see <a href="./references#CD008202-sec-0152" title="">Characteristics of included studies</a> and <a href="./references#CD008202-sec-0153" title="">Characteristics of excluded studies</a> for further details. </p> <section id="CD008202-sec-0070"> <h4 class="title">Results of the search</h4> <p>We carried out the search in June 2015 and identified a total of 471 citations. Once duplicates were removed 408 references were screened. From these 23 references were examined in detail (see <a href="./references#CD008202-sec-0153" title="">Characteristics of excluded studies</a>) and five studies (10 references) met the inclusion criteria for the review (<a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a>; <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a>; <a href="./references#CD008202-bbs2-0004" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;2(10):796‐803. ">Nwokoro 2014 (EVW only)</a>; <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a>; <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a>). <a href="#CD008202-fig-0001">Figure 1</a> provides details of the study search and assessment process. </p> <div class="figure" id="CD008202-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD008202-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD008202-sec-0071"> <h4 class="title">Included studies</h4> <p>Two studies contributed data on maintenance treatment (<a href="./references#CD008202-bbs2-0003" title="Rovi AH(MERCK) . Unpublished data from MERCK [personal communication]. Email to: M Brodlie 23 September 2012. ">Bisgaard 2005 (EVW only)</a>; <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a>) and four studies contributed data on intermittent LTRA treatment (<a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a>; <a href="./references#CD008202-bbs2-0004" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;2(10):796‐803. ">Nwokoro 2014 (EVW only)</a>; <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a>; <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a>). All were published as full text manuscripts. </p> <section id="CD008202-sec-0072"> <h5 class="title">Design</h5> <p>All of the studies were randomised, placebo‐controlled trials. <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a>; <a href="./references#CD008202-bbs2-0004" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;2(10):796‐803. ">Nwokoro 2014 (EVW only)</a> and <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> involved placebo and intermittent or maintenance LTRA (oral montelukast) treatment arms respectively. In the <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> study there were three groups; intermittent, maintenance and placebo treatment. The <a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a> study involved three groups, placebo, intermittent LTRA and intermittent budesonide; only data from the first two groups were included. The studies of intermittent therapy all involved parents or caregivers monitoring for symptoms in children and initiating treatment when an acute episode occurred. In all studies parents or caregivers were responsible for administering study medication to children. </p> </section> <section id="CD008202-sec-0073"> <h5 class="title">Population</h5> <p>A total of 3741 participants were recruited to the included studies. The review protocol set out to investigate the evidence of benefit from maintenance or intermittent LTRA treatment versus placebo in children aged one to six years presenting with EVW. </p> <p>One study included children aged from 2 to 14 years, but the study authors sent us outcome data for the number of participants experiencing one or more healthcare resource utilisation for children aged two to five years (<a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a>). In addition the <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> study included some infants aged six months to one year, although for several outcomes data were presented for children over two years of age only. The <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a> study included some children with interval symptoms. We contacted Merck and they provided the available specific data for participants exhibiting an EVW phenotype, with only intermittent symptoms (<a href="./references#CD008202-bbs2-0003" title="Rovi AH(MERCK) . Unpublished data from MERCK [personal communication]. Email to: M Brodlie 23 September 2012. ">Bisgaard 2005 (EVW only)</a>). In the <a href="./references#CD008202-bbs2-0043" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;10(2):796‐803. ">Nwokoro 2014</a> study specific data were obtained from the authors for children with an EVW phenotype only (<a href="./references#CD008202-bbs2-0004" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;2(10):796‐803. ">Nwokoro 2014 (EVW only)</a>). </p> <p>In our protocol we defined atopy as two or more positive radioallergosorbent (RAST) tests or skin prick tests (&gt; 3 mm wheal above control). The included studies were examined for atopic features using a variety of methods. In the <a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a> study, an Asthma Predictive Index (API) was used to give each child a negative or positive API status to reflect atopic status. Around 60% of children in the study had a positive API. Similarly 55% of children in the <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> study were API positive. In the <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a> study around a third of children had a positive specific‐IgE test for dog dander, cat dander, cockroach or <i>Alternaria alternata</i>. Of note in the <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> study, there was a relatively high incidence of participants with at least one allergic condition (seasonal or perennial rhinitis, allergic conjunctivitis or atopic dermatitis) and this differed significantly between LTRA treatment (80.4%) and placebo (65.7%) groups (P = 0.019). </p> </section> <section id="CD008202-sec-0074"> <h5 class="title">Interventions</h5> <p>All five included studies compared oral montelukast (4 mg once daily under the age of six years, 5 mg once daily over the age of six years) to placebo. Four studies (<a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a>; <a href="./references#CD008202-bbs2-0004" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;2(10):796‐803. ">Nwokoro 2014 (EVW only)</a>; <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a>; <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a>) investigated intermittent use of montelukast during symptomatic episodes and two studies (<a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a>, <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a>) investigated maintenance treatment. </p> </section> <section id="CD008202-sec-0075"> <h5 class="title">Outcomes</h5> <p>Outcome measures varied between all five studies such that the pooling of data was unfortunately limited (see <a href="./references#CD008202-sec-0152" title="">Characteristics of included studies</a> for more details). </p> </section> </section> <section id="CD008202-sec-0076"> <h4 class="title">Excluded studies</h4> <p>We excluded 13 studies and provide reasons for exclusion in the <a href="./references#CD008202-sec-0153" title="">Characteristics of excluded studies</a> section. In general studies were excluded because they included children with interval, multi‐trigger, 'asthma' type symptoms (rather than an EVW phenotype) or because they had not published primary data. </p> </section> </section> <section id="CD008202-sec-0077"> <h3 class="title">Risk of bias in included studies</h3> <p>A summary is provided in <a href="#CD008202-fig-0002">Figure 2</a> along with further details for individual studies in the <a href="./references#CD008202-sec-0152" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD008202-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008202-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008202-sec-0078"> <h4 class="title">Allocation</h4> <p>All five included studies had low risk of allocation bias with adequate random sequence generation and allocation concealment. Notably however in the <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> study, there was a statistically significant higher number of children in the montelukast group with rhinitis, eczema or at least one allergic condition than in the placebo group. These data were not available for the group of participants aged two to five years. </p> </section> <section id="CD008202-sec-0079"> <h4 class="title">Blinding</h4> <p>All five included studies were double‐blind with low risk of performance (blinding of participants and personnel) and detection (blinding of outcome assessment) bias. </p> </section> <section id="CD008202-sec-0080"> <h4 class="title">Incomplete outcome data</h4> <p>All studies reported loss to follow‐up and withdrawals, and performed an intention‐to‐treat analysis. In <a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a> there was a statistically significant higher number of dropouts (predominantly due to loss to follow‐up) in the montelukast (12.6%) compared to the placebo (2.1%) group (P = 0.04). In the <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a>, <a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a> and <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> studies 91%, 95% and 83% respectively of children randomised completed the study, with similar proportions in the treatment and placebo groups. </p> </section> <section id="CD008202-sec-0081"> <h4 class="title">Selective reporting</h4> <p>In all five included studies, there was insufficient information to permit a judgment about selective reporting (reporting bias). </p> </section> <section id="CD008202-sec-0082"> <h4 class="title">Other potential sources of bias</h4> <p>No other sources of bias were identified.</p> </section> </section> <section id="CD008202-sec-0083"> <h3 class="title" id="CD008202-sec-0083">Effects of interventions</h3> <p>See: <a href="./full#CD008202-tbl-0001"><b>Summary of findings for the main comparison</b> Maintenance LTRA compared to placebo for episodic viral wheeze in children</a>; <a href="./full#CD008202-tbl-0002"><b>Summary of findings 2</b> Intermittent LTRA compared to placebo for episodic viral wheeze in children</a> </p> <section id="CD008202-sec-0084"> <h4 class="title">Maintenance LTRA treatment</h4> <section id="CD008202-sec-0085"> <h5 class="title">Primary outcome</h5> <section id="CD008202-sec-0086"> <h6 class="title">Number of children with one or more viral‐induced episodes requiring treatment with oral corticosteroids </h6> <p>It was not possible to pool data for this outcome. The only trial reporting data was from the specific group of children with EVW (<a href="./references#CD008202-bbs2-0003" title="Rovi AH(MERCK) . Unpublished data from MERCK [personal communication]. Email to: M Brodlie 23 September 2012. ">Bisgaard 2005 (EVW only)</a>), n = 347, that participated in the <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a> study that was obtained directly from the pharmaceutical company. There was no statistically significant difference between maintenance montelukast versus placebo (OR 1.20, 95% CI 0.70 to 2.06, <a href="./references#CD008202-fig-0003" title="">Analysis 1.1</a>). Similarly there was no statistically significant difference between montelukast and placebo groups found for this outcome for all children (n = 549) randomised in the <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a> study (event rate/year of 0.53, 95% CI 0.40 to 0.70, vs. 0.64, 95% CI 0.47 to 0.88; relative rate reduction 0.82, 95% CI 0.54 to 1.25, rate reduction 17.5%, P = 0.368). </p> </section> </section> <section id="CD008202-sec-0087"> <h5 class="title">Secondary outcomes</h5> <section id="CD008202-sec-0088"> <h6 class="title">Number of participants experiencing one or more episodes requiring Emergency Department visit </h6> <p>It was not possible to pool data for this outcome. The only trial contributing data was the <a href="./references#CD008202-bbs2-0003" title="Rovi AH(MERCK) . Unpublished data from MERCK [personal communication]. Email to: M Brodlie 23 September 2012. ">Bisgaard 2005 (EVW only)</a> group (n = 347) where there was no statistically significant difference between maintenance montelukast treatment and placebo (OR 0.66, 95% CI 0.37 to 1.20, <a href="./references#CD008202-fig-0004" title="">Analysis 1.2</a>). This finding was similar to the conclusion drawn from all children (n = 549) randomised in the <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a> study, where data were not directly comparable. </p> </section> <section id="CD008202-sec-0089"> <h6 class="title">Number of participants experiencing one or more episodes requiring hospital admission</h6> <p>It was not possible to pool data for this outcome. The only trial contributing data was the <a href="./references#CD008202-bbs2-0003" title="Rovi AH(MERCK) . Unpublished data from MERCK [personal communication]. Email to: M Brodlie 23 September 2012. ">Bisgaard 2005 (EVW only)</a>, n = 347, group where there was no statistically significant difference between maintenance montelukast treatment and placebo (OR 0.65, 95% CI 0.23 to 1.87, <a href="./references#CD008202-fig-0005" title="">Analysis 1.3</a>). The rate of hospitalisation during the 12 month period was low across all children (n = 549) randomised in the <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a> study at 4.2% in the montelukast group and 5.8% in the placebo group. This finding was similar to the data, which were not in a directly comparable form, derived from all children randomised in the <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a> study. </p> </section> <section id="CD008202-sec-0090"> <h6 class="title">Number of participants experiencing one or more Healthcare Resource Utilisation</h6> <p>It was not possible to pool data for this outcome. <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> (n = 1100) was the only included study to report this outcome where there was no statistically significant difference from placebo (OR 0.85, 95% CI 0.68 to 1.07, <a href="./references#CD008202-fig-0006" title="">Analysis 1.4</a>). </p> </section> <section id="CD008202-sec-0091"> <h6 class="title">Number of participants experiencing one or more episode</h6> <p>It was not possible to pool data for this outcome. The only data identified for this outcome were from the <a href="./references#CD008202-bbs2-0003" title="Rovi AH(MERCK) . Unpublished data from MERCK [personal communication]. Email to: M Brodlie 23 September 2012. ">Bisgaard 2005 (EVW only)</a> group, n = 347, that showed no statistically significant difference between maintenance montelukast treatment and placebo (OR 0.68, 95% CI 0.44 to 1.05, <a href="./references#CD008202-fig-0007" title="">Analysis 1.5</a>). This finding was similar to the conclusion drawn from all children (n = 549) randomised in the <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a> study, where data were not directly comparable </p> </section> <section id="CD008202-sec-0092"> <h6 class="title">Mean symptom scores during episodes</h6> <p>It was not possible to pool data for this outcome. <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> (n = 1100) reported a composite score derived from the daily average symptom scores for wheeze, difficulty breathing, daytime cough and interference with daily activity during episodes for maintenance LTRA treatment in a <i>post hoc</i> analysis of children aged more than two years with at least one episode. The maximum symptom score possible was 14 and minimum score 0. There was a small improvement in symptom scores in the maintenance (MD ‐0.12, 95% CI ‐0.24 to 0, <a href="./references#CD008202-fig-0008" title="">Analysis 1.6</a>) treatment arm compared to placebo that reached statistical significance (P = 0.045). </p> </section> <section id="CD008202-sec-0093"> <h6 class="title">Mean use of rescue bronchodilator during episodes</h6> <p>It was not possible to pool data for this outcome. <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> (n = 1100) reported a small reduction in the least squares mean number of times per day a beta<sub>2</sub>‐agonist was used during episodes. The reduction was statistically lower for the maintenance (2.14, 95% CI 1.94 to 2.34) montelukast versus placebo (2.42, 95% CI 2.22 to 2.62) groups, (MD ‐0.29, 95% CI ‐0.58 to 0.00, P = 0.048, <a href="./references#CD008202-fig-0009" title="">Analysis 1.7</a>). </p> </section> <section id="CD008202-sec-0094"> <h6 class="title">New prescription or increased dose of inhaled corticosteroids or other maintenance add‐on therapy </h6> <p>No data were identified in the included studies relating to this outcome.</p> </section> <section id="CD008202-sec-0095"> <h6 class="title">Duration of episodes</h6> <p>No data were identified in the included studies relating to this outcome.</p> </section> <section id="CD008202-sec-0096"> <h6 class="title">Adverse health events</h6> <p>Included studies varied in the reporting of adverse effects and we chose to report these in a descriptive fashion (<a href="#CD008202-tbl-0003">Table 1</a>). No serious adverse effects were identified. </p> <div class="table" id="CD008202-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Reported adverse health events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reported adverse health events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not specified.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of drug‐related adverse experiences was similar in each group: 5% of patients in the montelukast group and 4.1% in the placebo group experienced at least one adverse event. There was one accidental overdose of montelukast that resulted in vomiting, after which the patient fully recovered. No patients in montelukast group discontinued because of an adverse experience considered by an investigator to be drug‐related. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008202-bbs2-0004" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;2(10):796‐803. ">Nwokoro 2014 (EVW only)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data only available for study as a whole (<a href="./references#CD008202-bbs2-0043" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;10(2):796‐803. ">Nwokoro 2014</a>). Only one serious adverse event was recorded, a skin reaction in the placebo group. Proportion of adverse events was similar between montelukast and placebo groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of possibly/probably drug‐related adverse experiences was similar in each group: 12.4% in the montelukast group and 11.4% in the placebo group. No serious drug‐related adverse experiences were reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of drug‐related adverse experiences was similar in each group and not felt to be "clinically meaningful": 0.5% of patients in the maintenance montelukast group; 1% in the intermittent montelukast group; and 0.9% in the placebo group experienced at least one adverse event. Three serious adverse effects were considered by the investigator to be drug‐related: pneumonia and asthma in a child receiving placebo and somnolence associated with overdose in a child receiving montelukast. </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD008202-sec-0097"> <h6 class="title">Withdrawals</h6> <p>There was no statistically significant difference in the number of withdrawals between the placebo and intervention (maintenance LTRA) groups (<a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a>, <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a>) (OR 0.87, 95% CI 0.66 to 1.13, n = 1729, <a href="./references#CD008202-fig-0010" title="">Analysis 1.8</a>). </p> </section> </section> </section> <section id="CD008202-sec-0098"> <h4 class="title">Intermittent LTRA treatment</h4> <section id="CD008202-sec-0099"> <h5 class="title">Primary outcome</h5> <section id="CD008202-sec-0100"> <h6 class="title">Number of children with one or more viral‐induced episodes requiring treatment with oral corticosteroids </h6> <p>Pooling of data from two studies (<a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a>, <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a>), showed no statistically significant reduction in the number of episodes requiring rescue oral steroids between intermittent montelukast and placebo (RR 0.85, 95% CI 0.64 to 1.14, n = 343, <a href="./references#CD008202-fig-0011" title="">Analysis 2.1</a>). </p> </section> </section> <section id="CD008202-sec-0101"> <h5 class="title">Secondary outcomes</h5> <section id="CD008202-sec-0102"> <h6 class="title">Number of participants experiencing one or more episodes requiring Emergency Department visit </h6> <p>It was not possible to pool data for this outcome. The individual study by <a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a> (n = 238) found no apparent beneficial effect (OR 1.00, 95% CI 0.49 to 2.02, <a href="./references#CD008202-fig-0012" title="">Analysis 2.2</a>). A similar outcome was reported by <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> (n = 220) in terms of the number of treated episodes with at least one Healthcare Resouce Utilisation for asthma requiring Emergency Department visit (<a href="./references#CD008202-fig-0013" title="">Analysis 2.3</a>). </p> </section> <section id="CD008202-sec-0103"> <h6 class="title">Number of participants experiencing one or more episodes requiring hospital admission</h6> <p>It was not possible to pool data for this outcome. In the individual <a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a> (n = 238) study there was no statistically significant reduction in admissions in the intermittent LTRA compared to placebo group (OR 0.73, 95% CI 0.20 to 2.73, <a href="./references#CD008202-fig-0014" title="">Analysis 2.4</a>). A similar outcome was reported by <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a>, n = 220, in terms of the number of treated episodes with at least one Healthcare Resource Utilisation for asthma requiring hospital admission (OR 0.74, 95% CI 0.32 to 1.72, <a href="./references#CD008202-fig-0015" title="">Analysis 2.5</a>). </p> </section> <section id="CD008202-sec-0104"> <h6 class="title">Number of participants experiencing one or more Healthcare Resource Utilisation</h6> <p>It was not possible to pool data for this outcome. <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> (n = 1102) was the only included study to report this outcome where there was a non‐significant difference from placebo (OR 0.96, 95% CI 0.76 to 1.21, <a href="./references#CD008202-fig-0016" title="">Analysis 2.6</a>). </p> <p>Data for a similar outcome were obtained from the authors of <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> for children aged two to five years, n = 176, in terms of number of episodes treated with study medication requiring healthcare resource utilisation that showed a significant benefit with intermittent montelukast versus placebo (OR 0.62, 95% CI 0.44 to 0.88). </p> </section> <section id="CD008202-sec-0105"> <h6 class="title">Rate of unscheduled medical attendances with wheeze</h6> <p>It was not possible to pool data for this outcome. In specific group data for children with an EVW phenotype in the <a href="./references#CD008202-bbs2-0004" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;2(10):796‐803. ">Nwokoro 2014 (EVW only)</a> study, n = 964, there was a statistically significant reduction in the risk ratio comparing intermittent montelukast to placebo (RR 0.83, 95% CI 0.71 to 0.98, P = 0.03, <a href="./references#CD008202-fig-0018" title="">Analysis 2.8</a>). </p> </section> <section id="CD008202-sec-0106"> <h6 class="title">Mean symptom scores during episodes</h6> <p>It was not possible to pool data for this outcome. <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> (n = 1,100) reported a composite score derived from the daily average symptom scores for wheeze, difficulty breathing, daytime cough and interference with daily activity during episodes for intermittent LTRA treatment in a <i>post hoc</i> analysis of children aged more than two years with at least one episode. Maximum symptom score possible was 14 with minimum being 0. There was a small statistically significant improvement in symptom scores in the intermittent LTRA arm compared to placebo (MD ‐0.11, 95% CI ‐0.23 to 0, P = 0.061, <a href="./references#CD008202-fig-0017" title="">Analysis 2.7</a>). </p> <p>In a broader age group <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a>, n = 220, reported median symptom scores from diary cards for montelukast treatment during episodes compared to placebo and found a modest but statistically significant reduction in the median total symptom score in the montelukast group (37, interquartile range, IQR, 19 to 62) compared to placebo (43, IQR 22 to 73), P = 0.049. </p> <p>The inability to obtain mean score and standard deviation prevented pooling of data of <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> with that of <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a>. </p> </section> <section id="CD008202-sec-0107"> <h6 class="title">Mean use of rescue bronchodilator during episodes</h6> <p>It was not possible to pool data for this outcome. <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> (n = 1100) found a small reduction in terms of the mean number of times per day a beta<sub>2</sub>‐agonist was used during episodes that was statistically significant for intermittent montelukast vs. placebo (MD ‐0.31, 95% CI ‐0.59 to ‐0.03, P = 0.028, <a href="./references#CD008202-fig-0019" title="">Analysis 2.9</a>). In the <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a>, n = 220, study, there was no difference in the cumulative number of puffs of beta<sub>2</sub>‐agonist used per episode (median of 36 puffs for montelukast and placebo groups). </p> </section> <section id="CD008202-sec-0108"> <h6 class="title">New prescription or increased dose of inhaled corticosteroids or other maintenance add‐on therapy </h6> <p>No data were identified in the included studies relating to this outcome.</p> </section> <section id="CD008202-sec-0109"> <h6 class="title">Duration of episodes</h6> <p>No significant group difference was observed in median duration of episodes by <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a>, n = 220, for intermittent montelukast (6.5 days, IQR 4 to 10) versus placebo (7 days, IQR 4 to 10), P = 0.3. </p> </section> <section id="CD008202-sec-0110"> <h6 class="title">Adverse health events</h6> <p>The included studies varied in reporting of adverse effects and we chose to report these in a descriptive fashion (<a href="#CD008202-tbl-0003">Table 1</a>). No serious adverse effects were identified. </p> </section> <section id="CD008202-sec-0111"> <h6 class="title">Withdrawals</h6> <p>There was no significant difference between the intermittent LTRA and placebo groups (OR 1.03, 95% CI 0.79 to 1.35, n = 1402, <a href="./references#CD008202-fig-0022" title="">Analysis 2.12</a>). While it was not possible to add the data for the <a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a> study of intermittent LTRA vs. placebo due to differences in reporting, there was no statistically significant difference between the placebo and montelukast group for drop outs (OR 6.65, 95% CI 0.84 to 52.79) or treatment failures (OR 0.99, 95% CI 0.37 to 2.64) in that study (n = 238). There were also no data available for the specific EVW phenotype group in the <a href="./references#CD008202-bbs2-0004" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;2(10):796‐803. ">Nwokoro 2014 (EVW only)</a> study, however withdrawals were similar between montelukast and placebo across the whole study. </p> </section> </section> </section> <section id="CD008202-sec-0112"> <h4 class="title">Maintenance vs. intermittent LTRA treatment</h4> <p>It was only possible to include data from the <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> (n = 1,102) study for this comparison. </p> <section id="CD008202-sec-0113"> <h5 class="title">Primary outcome</h5> <section id="CD008202-sec-0114"> <h6 class="title">Number of children with one or more viral‐induced episodes requiring treatment with oral corticosteroids </h6> <p>No data were available relating to this outcome.</p> </section> </section> <section id="CD008202-sec-0115"> <h5 class="title">Secondary outcomes</h5> <section id="CD008202-sec-0116"> <h6 class="title">Number of participants experiencing one or more episodes requiring Emergency Department visit </h6> <p>No data were available relating to this outcome.</p> </section> <section id="CD008202-sec-0117"> <h6 class="title">Number of participants experiencing one or more episodes requiring hospital admission</h6> <p>No data were available relating to this outcome.</p> </section> <section id="CD008202-sec-0118"> <h6 class="title">Number of participants experiencing one or more Healthcare Resource Utilisation</h6> <p>There was no significant difference between maintenance and intermittent treatment groups for this outcome (OR 0.88, 95% CI 0.70 to 1.11, <a href="./references#CD008202-fig-0023" title="">Analysis 3.1</a>), n = 1102. </p> </section> <section id="CD008202-sec-0119"> <h6 class="title">Mean symptom scores during episodes</h6> <p>There was no significant difference between maintenance and intermittent treatment groups for this outcome (MD ‐0.01, 95% CI ‐0.12 to 0.1, P = 0.86, <a href="./references#CD008202-fig-0024" title="">Analysis 3.2</a>), n = 1102. </p> </section> <section id="CD008202-sec-0120"> <h6 class="title">Mean use of rescue bronchodilator during episodes</h6> <p>There was no significant difference between maintenance and intermittent treatment groups for this outcome (MD 0.03, 95% CI ‐0.24 to 0.30, P = 0.83, <a href="./references#CD008202-fig-0025" title="">Analysis 3.3</a>), n = 1102. </p> </section> <section id="CD008202-sec-0121"> <h6 class="title">New prescription or increased dose of inhaled corticosteroids or other maintenance add‐on therapy </h6> <p>No data were available relating to this outcome.</p> </section> <section id="CD008202-sec-0122"> <h6 class="title">Duration of episodes</h6> <p>No data were available relating to this outcome.</p> </section> <section id="CD008202-sec-0123"> <h6 class="title">Adverse health events</h6> <p>No data were available relating to this outcome.</p> </section> <section id="CD008202-sec-0124"> <h6 class="title">Withdrawals</h6> <p>There was no significant difference between maintenance and intermittent treatment groups for this outcome (OR 0.95, 95% CI 0.70 to 1.28, <a href="./references#CD008202-fig-0026" title="">Analysis 3.4</a>), n = 1102. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008202-sec-0125" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008202-sec-0125"></div> <section id="CD008202-sec-0126"> <h3 class="title" id="CD008202-sec-0126">Summary of main results</h3> <p>This systematic review examined the available evidence for the effectiveness of maintenance or intermittent LTRA treatment in children aged one to six years with EVW published up to June 2015. We included five studies in the review with a total of 3741 participants. Two studies contributed data on maintenance treatment (<a href="./references#CD008202-bbs2-0003" title="Rovi AH(MERCK) . Unpublished data from MERCK [personal communication]. Email to: M Brodlie 23 September 2012. ">Bisgaard 2005 (EVW only)</a>, <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a>) and four studies contributed data on intermittent LTRA treatment (<a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a>, <a href="./references#CD008202-bbs2-0004" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;2(10):796‐803. ">Nwokoro 2014 (EVW only)</a>, <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> and <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a>). </p> <p>For maintenance LTRA, we failed to find evidence of clinical benefit for the primary outcome of the review, that is, a reduction in the number of children with one or more viral‐induced episodes requiring treatment with oral corticosteroids. The only data identified for this outcome were from the group of children with EVW (<a href="./references#CD008202-bbs2-0003" title="Rovi AH(MERCK) . Unpublished data from MERCK [personal communication]. Email to: M Brodlie 23 September 2012. ">Bisgaard 2005 (EVW only)</a>) that were included in the <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a> study; however findings on the specific group analysis are concordant with that of all randomised children, irrespective of phenotype. Furthermore, no other statistically significant differences were identified between maintenance treatment and placebo groups for any of the secondary outcomes examined. It is important to note that, with only two trials contributing data, the power was limited, and because of differences in outcome selection and reporting between studies, pooling was seldom possible. In the study by <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a>, maintenance montelukast treatment was associated with a statistically significant, yet clinically modest, reduction in the severity of symptoms derived from a composite score (daily average of wheeze, difficulty breathing, daytime cough and interference with daily living score; maximum score 14) during wheezing episodes compared to placebo. In the <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a> study, there was a statistically significant reduction in the rate of exacerbations (all severity) in the maintenance montelukast versus placebo groups. </p> <p>We also found no evidence of clinical benefit for intermittent LTRA treatment for the primary outcome of the review, a reduction in the number of children with one or more viral‐induced episodes requiring treatment with oral corticosteroids. This was based on pooled data from two studies (<a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a>, <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a>). Specific group data obtained from the authors of the <a href="./references#CD008202-bbs2-0043" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;10(2):796‐803. ">Nwokoro 2014</a> study for children with an EVW phenotype (<a href="./references#CD008202-bbs2-0004" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;2(10):796‐803. ">Nwokoro 2014 (EVW only)</a>) showed a small but statistically significant reduction in the rate ratio of unscheduled medical attendances with wheeze in the intermittent montelukast versus placebo group. There were no statistically significant differences found between intermittent LTRA treatment and placebo for any other secondary outcomes; yet, with the exception of withdrawals, only one trial contributed to each outcome; as our ability to pool data from two or more trials was limited by differences in outcome selection and reporting between studies. In two trials (<a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a> and <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a>) there was a statistically significant reduction in the severity of symptoms during episodes favouring intermittent LTRA over placebo, but the data could not be pooled due to reporting differences; yet each reduction was quite modest and of questionable clinical importance (<a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a>: trouble breathing score, area under curve, for 14 days after initiation of therapy and interference with activity score and in <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> total diary card symptom score). </p> <p>The comparison between maintenance and intermittent LTRA treatment was limited by data being contributed from only one study (<a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a>). No data were identified for the primary outcome of the review. We found no evidence of any statistically significant differences between maintenance and intermittent LTRA treatment for the following secondary outcomes of this review: participants experiencing one or more healthcare resource utilisation, symptoms during episodes, mean daily use of bronchodilator during episodes or total number of withdrawals. </p> <p>The included studies varied in the reporting of adverse effects and we chose to report these in a descriptive fashion. No serious adverse effects were noted, however. In keeping with the wider literature and clinical experience, LTRA treatment was generally well tolerated compared to placebo in included studies, but firm conclusions cannot be drawn due to the paucity of data. </p> </section> <section id="CD008202-sec-0127"> <h3 class="title" id="CD008202-sec-0127">Overall completeness and applicability of evidence</h3> <p>Each study included in the review involved montelukast but differed in terms of the choice and reporting of outcomes, which limited our ability to pool data between two or more studies, including for the main outcome in all three comparisons. </p> <p>The biggest threat to the validity of the results arises from the possibility that some studies may have included children with multi‐trigger wheeze rather than children with only isolated EVW. The broad phenotypes of children who wheeze (EVW versus multi‐trigger atopic asthma) may be particularly challenging to differentiate in the pre‐school age group, furthermore distinctions are not fixed and phenotypes may vary over time (<a href="./references#CD008202-bbs2-0026" title="BushA . Practice imperfect ‐ treatment for wheezing in preschoolers. New England Journal of Medicine2009;360(4):409‐410. ">Bush 2009</a>, <a href="./references#CD008202-bbs2-0031" title="DucharmeFM , MorinJ , DavisGM , GingrasJ , NoyaFJ . High physician adherence to phenotype‐specific asthma guidelines, but large variability in phenotype assessment in children. Current Medical Research and Opinion2012;28(9):1561‐70. ">Ducharme 2012</a>). We tried to avoid this by careful inclusion of only studies focusing on EVW involving children free of symptoms between episodes. However this did not eliminate the presence of children with other atopic conditions in the studies and it is possible that such children were more likely to have had unrecognised multi‐trigger atopic asthma. For example in the <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> study, 73% of participants had at least one allergic condition (seasonal or perennial rhinitis, allergic conjunctivitis or atopic dermatitis). For the <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a> study, we obtained unpublished group data specifically relating to carefully characterised children with only intermittent symptoms (<a href="./references#CD008202-bbs2-0003" title="Rovi AH(MERCK) . Unpublished data from MERCK [personal communication]. Email to: M Brodlie 23 September 2012. ">Bisgaard 2005 (EVW only)</a>). These data were not available for all of the outcomes reported in the primary paper, however where comparisons were possible, results were similar between all of the children randomised in the <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a> study and those just with apparent EVW (<a href="./references#CD008202-bbs2-0003" title="Rovi AH(MERCK) . Unpublished data from MERCK [personal communication]. Email to: M Brodlie 23 September 2012. ">Bisgaard 2005 (EVW only)</a>). Similarly we obtained group data for children with a specific EVW phenotype in the <a href="./references#CD008202-bbs2-0004" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;2(10):796‐803. ">Nwokoro 2014 (EVW only)</a> study of intermittent montelukast, however this trial contributed to one outcome, namely the rate of unscheduled medical attendance with wheeze. </p> <p>In our protocol, we set out to include only studies involving children with EVW aged one to six years. The <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> study included some infants aged between six months and one year and the <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> study included some older children, although we did obtain data from the authors for children aged two to five years old for the number of participants experiencing one or more healthcare resource utilisation. </p> <p>In summary, limitations of the evidence as it stands presently include the relatively small number of studies, potential heterogeneity in the phenotype of participants within and across trials, and differences in selection and reporting of outcomes between studies that seriously limited our ability to pool data for most outcomes. Overall however, the included studies arguably involved the sort of pre‐school children who wheeze with colds that clinicians encounter on a daily basis in their clinics and emergency departments. </p> <p>In the review protocol, we set out to perform subgroup analyses of atopic children (defined as two or more positive RAST tests or skin prick tests &gt; 3 mm wheal above control) and also children aged one to three years and four to six years respectively. Due to incomplete reporting, these subgroup analyses were not performed. Instead, several studies reported the Asthma Predictive Index (API) of their patients; the API includes atopy as one of its criteria but a child may have a positive API index without meeting our protocol definition of atopy. In the <a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a> study, which enrolled children with a negative or positive API status, greater symptomatic benefit from episodic montelukast use was observed in children with a positive API status in a subgroup analysis. In the <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a> study of maintenance montelukast treatment, no significant subgroup interaction was found for children with atopic features (atopic dermatitis, allergic rhinitis, raised eosinophil count or &gt; 1 positive RAST) on the primary outcome of exacerbation rate; these data were not available for the <a href="./references#CD008202-bbs2-0003" title="Rovi AH(MERCK) . Unpublished data from MERCK [personal communication]. Email to: M Brodlie 23 September 2012. ">Bisgaard 2005 (EVW only)</a> group. In the study by <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> children were also categorised for API status at entry, but outcome data was not provided by API subgroups. <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> found no significant differences in their primary end‐point (healthcare resource utilisation) for a number of pre‐defined subgroup analyses relating to atopic status (history of rhinitis, family history of asthma or IgE &gt; 130 units/mL) in their study of intermittent montelukast versus placebo. These data were not available for children aged two to five in the <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> study. In summary, the current data would suggest that markers of atopy (including API) did not appear to modify the magnitude of effect of LTRA (which was minimal or absent in the study group). </p> <p>We were also unable to identify any reported data on a number of secondary outcomes of clinical interest, for example increase in inhaled corticosteroid dose or other maintenance add‐on therapy. </p> </section> <section id="CD008202-sec-0128"> <h3 class="title" id="CD008202-sec-0128">Quality of the evidence</h3> <p>The five included studies were of good methodological quality, in that they were all randomised, double‐blind, placebo‐controlled trials with a low risk of bias in terms of random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), and outcome assessment (detection bias). The percentage of children randomised who completed the studies ranged from 83% to 95% and an intention‐to‐treat analysis was performed in all studies. In all five studies, there was insufficient information to permit a judgment about selective reporting (reporting bias). </p> <p>Data from specific groups of participants from three studies were selected in the review, which may have limited the benefits of randomisation. </p> <p>As outlined above in the <a href="#CD008202-sec-0127">Overall completeness and applicability of evidence</a> section, there are other potential sources of bias due to the characteristics of the participants in some of the included studies. This included an increased proportion of males in the montelukast group in the <a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a> study, increased proportion of children with an atopic condition in the montelukast compared to the placebo groups in the <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> study, and the inclusion of some children with interval symptoms (37% of participants) in the <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a> study. In addition, the <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> study included some infants (16% of participants) aged six to 12 months and the <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> study some children (20% of participants) aged six to 14 years. In the case of <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a>, we obtained specific group data as far as was available for the 63% of children that participated with an apparently pure EVW phenotype (<a href="./references#CD008202-bbs2-0003" title="Rovi AH(MERCK) . Unpublished data from MERCK [personal communication]. Email to: M Brodlie 23 September 2012. ">Bisgaard 2005 (EVW only)</a>) and the authors of <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> also provided us with the number of participants experiencing one or more healthcare resource utilisation for the subset of children aged two to five years representing 80% of their randomised participants. The authors of the <a href="./references#CD008202-bbs2-0004" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;2(10):796‐803. ">Nwokoro 2014 (EVW only)</a> study provided us with specific group data for children with an EVW phenotype representing 71% of their randomised children. We aggregated data in children aged one to six years with seemingly intermittent wheeze induced by viral respiratory tract infections, but we cannot firmly confirm whether there might still be contamination with children with multi‐trigger wheeze with or without atopic symptoms, in part due to evolving definitions of persistent asthma over the past decade when the trials were conducted. </p> <p>In other words, the quality of the data was good, although the strength of the evidence was limited by the paucity of trials comparing maintenance (or intermittent) LTRA to placebo with only one small trial with head‐to‐head comparison between maintenance and intermittent LTRA. Moreover, in two of these three comparisons, there was no, or only one, trial reporting our <i>a priori</i> primary outcome, thus preventing aggregation. Overall where comparisons were possible the GRADE classification (<a href="./references#CD008202-bbs2-0048" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , GuyattGH . Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>) was judged to be moderate (see <a href="./full#CD008202-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./full#CD008202-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD008202-sec-0129"> <h3 class="title" id="CD008202-sec-0129">Potential biases in the review process</h3> <p>This systematic review addressed a focused research question and used pre‐specified inclusion criteria and methodology to search, select, appraise and analyse data from eligible studies. We attempted, throughout the review process, to minimise any potential biases, but as with all systematic reviews, the possibility of publication bias should be considered as a potential threat to validity. We followed the review process recommended by the Cochrane Airway Group strictly, however and this included a rigorous trial search strategy and a check of reference lists of all primary studies and review articles for any additional references. We also contacted authors of identified trials and manufacturers and experts in the field, to ask them to identify other published and unpublished studies, hence we believe that the risk of such a bias affecting the results has been minimised. Multiple individuals were involved at each stage of the process with a consensus being reached where necessary, further limiting subjectivity and errors. </p> <p>Due to the limited number of studies included in the systematic review, few outcomes aggregated the data from two or more trials, thus limiting the power to detect a clinically important group difference. </p> <p>The choice of the primary outcome of this systematic review (the number of children with one or more episodes requiring treatment with rescue oral corticosteroids) may be challenged. Several studies have questioned this therapy in children with EVW, although the reasons for apparent non‐effectiveness may be due to misclassification in the diagnosis (e.g. inclusion of bronchiolitis) or studies exploring this approach as preventative use of oral steroids at the onset of a cold rather than the therapeutic use by a physician for a moderate or severe exacerbation (<a href="./references#CD008202-bbs2-0035" title="GuilbertTW , BacharierLB . Controversies in the treatment of the acutely wheezing infant. American Journal of Respiratory and Critical Care Medicine2011;183:1284‐85. ">Guilbert 2011</a>). However, perhaps pre‐school viral wheeze may be less responsive to oral steroids than in older children, this is currently being examined in a large cohort study of children with moderate and severe asthma (NCT: 02013076). Future findings may or may not eventually challenge this practice in the acute management of children with moderate or severe exacerbations (<a href="./references#CD008202-bbs2-0045" title="PanickarJ , LakhanpaulM , LambertPC , KeniaP , StephensonT , SmythA , et al. Oral prednisolone for preschool children with acute virus‐induced wheezing. New England Journal of Medicine2009;360(4):329‐38. ">Panickar 2009</a>, <a href="./references#CD008202-bbs2-0026" title="BushA . Practice imperfect ‐ treatment for wheezing in preschoolers. New England Journal of Medicine2009;360(4):409‐410. ">Bush 2009</a> and <a href="./references#CD008202-bbs2-0035" title="GuilbertTW , BacharierLB . Controversies in the treatment of the acutely wheezing infant. American Journal of Respiratory and Critical Care Medicine2011;183:1284‐85. ">Guilbert 2011</a>). Nevertheless, the intention to use rescue oral steroids remains a recognised marker of a moderate or severe exacerbation targeted by our primary outcome. The findings derived from our primary outcome are supported by the secondary outcomes of the review largely showing no evidence of treatment benefit. </p> </section> <section id="CD008202-sec-0130"> <h3 class="title" id="CD008202-sec-0130">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge, this is the first systematic review of LTRA in the management of EVW. </p> <p>Although the findings of included studies of LTRAs in EVW are not easy to compare because of differences in their selection of the main outcome, they are nonetheless broadly consistent with the conclusions of this systematic review. <a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a> in the PREvention of Viral Induced Asthma (PREVIA) study found that daily administered montelukast over 12 months reduced the primary endpoint of their trial namely, the number of asthma exacerbations of any severity, by approximately 32% when compared with placebo; however, it did not reduce the need for rescue oral steroids. Montelukast was also associated with a significantly longer time to first exacerbation (any severity) and reduced the overall rate of rescue ICS usage, suggesting some efficacy with regard to mild exacerbations in this mixed population of children with persistent and EVW. <a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> concluded that episode‐driven montelukast for seven days or until 48 hours after the resolution of symptoms resulted in a significant reduction in healthcare resource utilisation (primary care visits and emergency department visits), missed school or work days, and improved symptom scores. However, there was no significant effect on bronchodilator or rescue oral prednisolone use, again suggesting a benefit for children with mild exacerbations in this mixed population of preschool and school‐aged children with persistent and EVW. <a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a> in the Acute Intervention Management Strategies (AIMS) study, showed that episodic montelukast was not significantly better than placebo when added to rescue salbutamol for their primary outcome of episode‐free days or for rescue oral steroids over a one‐year study period. However, montelukast significantly improved symptoms and activity scores during exacerbations. Interestingly, children with positive API scores appeared to experience a greater clinical benefit from intermittent montelukast than those with negative API scores, but this is derived from a subgroup analysis and must thus be interpreted with caution. <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> found that neither daily nor intermittent montelukast reduced the number of episodes culminating in an asthma attack (primary outcome). Maintenance montelukast treatment was associated with a reduction in symptoms over the 12‐day treatment period during episodes. Both intermittent and daily treatment was associated with reduced beta‐agonist use. In the <a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> study, children with a positive API responded better to montelukast. In summary, as discussed above, the presence of children with a positive API in many of the included studies suggests possible misclassification of children as EVW who actually had undiagnosed multi‐trigger wheeze or atopic asthma. In the <a href="./references#CD008202-bbs2-0043" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;10(2):796‐803. ">Nwokoro 2014</a> (WAIT) study of intermittent montelukast, there was no significant difference in unscheduled medical attendances for wheezing episodes between montelukast and placebo groups (mean 2.0 [SD 2.6] vs. 2.3 [2.7], incident rate ratio 0.88 [95% CI 0.77 to 1.01], P = 0.06) overall. Interestingly there was a statistically significant benefit detected in the sub‐stratum of children with 5/5 <i>ALOX5</i> promoter genotype suggesting that these children may represent a montelukast‐responsive group. We have also identified a statistically significant reduction in the specific group of children with an EVW phenotype. These reviews and independent trials may suggest that daily or intermittent montelukast may be modestly effective for the prevention of mild, but less so for moderate or severe, exacerbations. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008202-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD008202-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/full#CD008202-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008202-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/full#CD008202-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Maintenance LTRA versus placebo, Outcome 1 Number of participants experiencing one or more episode requiring treatment with oral steroids." data-id="CD008202-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Maintenance LTRA versus placebo, Outcome 1 Number of participants experiencing one or more episode requiring treatment with oral steroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Maintenance LTRA versus placebo, Outcome 2 Number of participants experiencing one or more episodes requiring ED visit." data-id="CD008202-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Maintenance LTRA versus placebo, Outcome 2 Number of participants experiencing one or more episodes requiring ED visit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Maintenance LTRA versus placebo, Outcome 3 Number of participants experiencing one or more episodes requiring hospital admission." data-id="CD008202-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Maintenance LTRA versus placebo, Outcome 3 Number of participants experiencing one or more episodes requiring hospital admission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Maintenance LTRA versus placebo, Outcome 4 Number of participants experiencing one or more HRU." data-id="CD008202-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Maintenance LTRA versus placebo, Outcome 4 Number of participants experiencing one or more HRU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Maintenance LTRA versus placebo, Outcome 5 Number of participants experiencing one or more asthma exacerbation episodes." data-id="CD008202-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Maintenance LTRA versus placebo, Outcome 5 Number of participants experiencing one or more asthma exacerbation episodes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Maintenance LTRA versus placebo, Outcome 6 Symptoms during episode." data-id="CD008202-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Maintenance LTRA versus placebo, Outcome 6 Symptoms during episode.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Maintenance LTRA versus placebo, Outcome 7 Mean daily use of rescue bronchodilator during episodes." data-id="CD008202-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Maintenance LTRA versus placebo, Outcome 7 Mean daily use of rescue bronchodilator during episodes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Maintenance LTRA versus placebo, Outcome 8 Withdrawals." data-id="CD008202-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Maintenance LTRA versus placebo, Outcome 8 Withdrawals.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermittent LTRA versus placebo, Outcome 1 Number of participants experiencing one or more episode requiring treatment with oral steroids." data-id="CD008202-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Intermittent LTRA versus placebo, Outcome 1 Number of participants experiencing one or more episode requiring treatment with oral steroids. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermittent LTRA versus placebo, Outcome 2 Number of participants experiencing one or more episodes requiring ED visit." data-id="CD008202-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Intermittent LTRA versus placebo, Outcome 2 Number of participants experiencing one or more episodes requiring ED visit. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermittent LTRA versus placebo, Outcome 3 Absolute number of treated episodes with at least one HRU ED visits." data-id="CD008202-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Intermittent LTRA versus placebo, Outcome 3 Absolute number of treated episodes with at least one HRU ED visits. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermittent LTRA versus placebo, Outcome 4 Number of participants experiencing one or more episodes requiring hospital admission." data-id="CD008202-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Intermittent LTRA versus placebo, Outcome 4 Number of participants experiencing one or more episodes requiring hospital admission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermittent LTRA versus placebo, Outcome 5 Absolute number of treated episodes with at least one HRU hospital admissions." data-id="CD008202-fig-0015" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Intermittent LTRA versus placebo, Outcome 5 Absolute number of treated episodes with at least one HRU hospital admissions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermittent LTRA versus placebo, Outcome 6 Number of participants experiencing one or more HRU." data-id="CD008202-fig-0016" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Intermittent LTRA versus placebo, Outcome 6 Number of participants experiencing one or more HRU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermittent LTRA versus placebo, Outcome 7 Symptoms during episode." data-id="CD008202-fig-0017" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Intermittent LTRA versus placebo, Outcome 7 Symptoms during episode.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermittent LTRA versus placebo, Outcome 8 Unscheduled medical attendances with wheeze (Rate ratio)." data-id="CD008202-fig-0018" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Intermittent LTRA versus placebo, Outcome 8 Unscheduled medical attendances with wheeze (Rate ratio). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermittent LTRA versus placebo, Outcome 9 Mean daily use of rescue bronchodilator during episodes." data-id="CD008202-fig-0019" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Intermittent LTRA versus placebo, Outcome 9 Mean daily use of rescue bronchodilator during episodes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermittent LTRA versus placebo, Outcome 10 Days of OCS use per participant." data-id="CD008202-fig-0020" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Intermittent LTRA versus placebo, Outcome 10 Days of OCS use per participant.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermittent LTRA versus placebo, Outcome 11 Absolute number of treated episodes with at least one HRU GP visits." data-id="CD008202-fig-0021" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Intermittent LTRA versus placebo, Outcome 11 Absolute number of treated episodes with at least one HRU GP visits. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Intermittent LTRA versus placebo, Outcome 12 Withdrawals." data-id="CD008202-fig-0022" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Intermittent LTRA versus placebo, Outcome 12 Withdrawals.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Maintenance LTRA vs. intermittent LTRA, Outcome 1 Number of participants experiencing one or more HRU." data-id="CD008202-fig-0023" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Maintenance LTRA vs. intermittent LTRA, Outcome 1 Number of participants experiencing one or more HRU. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Maintenance LTRA vs. intermittent LTRA, Outcome 2 Symptoms during episode." data-id="CD008202-fig-0024" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Maintenance LTRA vs. intermittent LTRA, Outcome 2 Symptoms during episode.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Maintenance LTRA vs. intermittent LTRA, Outcome 3 Mean daily use of rescue bronchodilator during episodes." data-id="CD008202-fig-0025" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Maintenance LTRA vs. intermittent LTRA, Outcome 3 Mean daily use of rescue bronchodilator during episodes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008202-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/urn:x-wiley:14651858:media:CD008202:CD008202-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_t/tCD008202-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Maintenance LTRA vs. intermittent LTRA, Outcome 4 Total number of withdrawals." data-id="CD008202-fig-0026" src="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Maintenance LTRA vs. intermittent LTRA, Outcome 4 Total number of withdrawals.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/media/CDSR/CD008202/image_n/nCD008202-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008202-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Maintenance LTRA compared to placebo for episodic viral wheeze in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Maintenance LTRA compared to placebo for episodic viral wheeze in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> episodic viral wheeze in children<br/> <b>Settings:</b> community and hospitals<br/> <b>Intervention: m</b> aintenance LTRA<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Maintenance LTRA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants experiencing one or more episode requiring treatment with oral steroids </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>173 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>201 per 1000<br/> (128 to 302) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.20<br/> (0.70 to 2.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>347<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants experiencing one or more episodes requiring ED visit</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>179 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000<br/> (75 to 208) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.66<br/> (0.37 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>347<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants experiencing one or more episodes requiring hospital admission</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>52 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000<br/> (12 to 93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.65<br/> (0.23 to 1.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>347<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals ‐ Total number of withdrawals</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>154 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>137 per 1000<br/> (107 to 171) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.87<br/> (0.66 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1729<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None reported, so not possible to assess the risks of serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Confidence interval cannot rule out important benefit or harm. </p> <p><sup>2</sup>Note potential heterogeneity in the phenotype of participants within and across studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Maintenance LTRA compared to placebo for episodic viral wheeze in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/full#CD008202-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008202-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intermittent LTRA compared to placebo for episodic viral wheeze in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Intermittent LTRA compared to placebo for episodic viral wheeze in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> episodic viral wheeze in children<br/> <b>Settings:</b> community and hospitals<br/> <b>Intervention: i</b> ntermittent LTRA<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Intermittent LTRA</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants experiencing one or more episode requiring treatment with oral steroids </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>336 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>285 per 1000<br/> (215 to 382) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.85<br/> (0.64 to 1.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>343<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants experiencing one or more episodes requiring ED visit</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>553 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>553 per 1000<br/> (378 to 714) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.00<br/> (0.49 to 2.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants experiencing one or more episodes requiring hospital admission</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 1000<br/> (18 to 203) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.73<br/> (0.20 to 2.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals ‐ Total number of withdrawals</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>183 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>188 per 1000<br/> (151 to 232) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.03<br/> (0.79 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1402<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None reported, so not possible to assess the risks of serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Confidence interval cannot rule out important benefit or harm. </p> <p><sup>2</sup>Note potential heterogeneity in the phenotype of participants within and across studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Intermittent LTRA compared to placebo for episodic viral wheeze in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/full#CD008202-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008202-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Reported adverse health events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reported adverse health events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008202-bbs2-0001" title="BacharierLB , PhillipsBR , ZeigerRS , SzeflerSJ , MartinezFD , LemanskeRF , et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate‐to‐severe intermittent wheezing. Journal of Allergy and Clinical Immunology2008;122:1127‐35. ">Bacharier 2008a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not specified.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008202-bbs2-0002" title="BisgaardH , GillesL , MentenJ , TozziC , PolosP . Montelukast reduces rescue medication use in viral‐induced asthma exacerbations. American Thoracic Society 100th International Conference, May 21‐26, 2004, Orlando. 2004; Vol. A53, issue Poster C72. BisgaardH , SwernAS , DassSB , PolosPG . Effect of montelukast on asthma exacerbation rates in pediatric patients with or without prior oral steroid use: a post hoc analysis of the PREVIA trial of viral‐associated asthma. American Thoracic Society International Conference, May 18‐23, 2007, San Francisco, California, USA. 2007; Vol. Poster #733. BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ at el . Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory and Critical Care Medicine2005;171(4):315‐22. BisgaardH , ZielenS , GilesL , MentenJ , PolosPG . Montelukast and the prevention of viral induced asthma (The PREVIA Study). European Respiratory Journal2003;22(Suppl 45):Abstract No 3343. ">Bisgaard 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of drug‐related adverse experiences was similar in each group: 5% of patients in the montelukast group and 4.1% in the placebo group experienced at least one adverse event. There was one accidental overdose of montelukast that resulted in vomiting, after which the patient fully recovered. No patients in montelukast group discontinued because of an adverse experience considered by an investigator to be drug‐related. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008202-bbs2-0004" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;2(10):796‐803. ">Nwokoro 2014 (EVW only)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data only available for study as a whole (<a href="./references#CD008202-bbs2-0043" title="NwokoroN , PandyaH , TurnerS , EldridgeS , GriffithsCJ , VulliamyT , et al. Intermittent montelukast in children aged 10 months to 5 years with wheeze (WAIT trial): a multicentre, randomised, placebo‐controlled trial. The Lancet Respiratory Medicine2014;10(2):796‐803. ">Nwokoro 2014</a>). Only one serious adverse event was recorded, a skin reaction in the placebo group. Proportion of adverse events was similar between montelukast and placebo groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008202-bbs2-0005" title="Merck . A study to determine the effect of montelukast sodium as an episode modifier in the treatment of infrequent episodic asthma in children. Clinicaltrials.Gov2005. RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine2007;175(4):323‐9. ">Robertson 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of possibly/probably drug‐related adverse experiences was similar in each group: 12.4% in the montelukast group and 11.4% in the placebo group. No serious drug‐related adverse experiences were reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008202-bbs2-0006" title="ValovirtaE , BozaM , RobertsonC , VerbruggenN , SmugarS , KnorrB , et al. Intermittent and daily montelukast versus placebo for treating episodic asthma in children 6 months to 5 years of age. European Journal of Allergy and Clinical Immunology. 29th Congress of the European Academy of Allergy and Clinical Immunology, EAACI London United Kingdom. 2010. ValovirtaE , BozaML , RobertsonCF , VerbruggenN , SmugarSS , NelsenLM , et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Annals of Allergy, Asthma &amp; Immunology2011;106(6):518‐26. ">Valovirta 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proportion of drug‐related adverse experiences was similar in each group and not felt to be "clinically meaningful": 0.5% of patients in the maintenance montelukast group; 1% in the intermittent montelukast group; and 0.9% in the placebo group experienced at least one adverse event. Three serious adverse effects were considered by the investigator to be drug‐related: pneumonia and asthma in a child receiving placebo and somnolence associated with overdose in a child receiving montelukast. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Reported adverse health events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/full#CD008202-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008202-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Maintenance LTRA versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants experiencing one or more episode requiring treatment with oral steroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants experiencing one or more episodes requiring ED visit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Number of participants experiencing one or more episodes requiring hospital admission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants experiencing one or more HRU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Number of participants experiencing one or more asthma exacerbation episodes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Symptoms during episode <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Mean daily use of rescue bronchodilator during episodes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.66, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Maintenance LTRA versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008202-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Intermittent LTRA versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants experiencing one or more episode requiring treatment with oral steroids <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.64, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Number of participants experiencing one or more episodes requiring ED visit <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Absolute number of treated episodes with at least one HRU ED visits <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of participants experiencing one or more episodes requiring hospital admission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Absolute number of treated episodes with at least one HRU hospital admissions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Number of participants experiencing one or more HRU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Symptoms during episode <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Unscheduled medical attendances with wheeze (Rate ratio) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Mean daily use of rescue bronchodilator during episodes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Days of OCS use per participant <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Absolute number of treated episodes with at least one HRU GP visits <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Withdrawals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1686</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.84, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Dropouts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.65 [0.84, 52.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Treatment failures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.37, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Total number of witdrawals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.79, 1.35]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Intermittent LTRA versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008202-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Maintenance LTRA vs. intermittent LTRA</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Number of participants experiencing one or more HRU <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Symptoms during episode <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean daily use of rescue bronchodilator during episodes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total number of withdrawals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Maintenance LTRA vs. intermittent LTRA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008202.pub2/references#CD008202-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008202.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD008202-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD008202-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008202-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD008202-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD008202-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD008202-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008202-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008202\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008202\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008202\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008202\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008202\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008202\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008202\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008202\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008202\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008202\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008202\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008202\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008202\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008202\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008202\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008202\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008202\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008202\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=ZCrlluee&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008202.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008202.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008202.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008202.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008202.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728017498"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008202.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728017505"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008202.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eba37cd24937f',t:'MTc0MDcyODAxNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 